跳到正文
← 返回论文列表与筛选
阅读说明

本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。

DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。

引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。

关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。

分类依据与纠错

AI 根据所提供的论文材料归类:摘要明确研究随机化后选择、主层中的生存因果效应,并使用单调性假设开展敏感性分析。

反馈分类问题

正在核对关联版本…

代码、数据与补充材料

正在核对对应版本的资源…

关注这篇论文的作者
Bryan E Shepherd
Peter B Gilbert
Thomas Lumley

随机化后所选子群中生存结局比较的敏感性分析

研究问题
当结局仅在随机化后形成的子群中存在时,如何比较疫苗与安慰剂对无论分配何种处理都会感染者的后续生存概率影响?
方法与思路
作者针对始终感染主层定义生存因果效应,在疫苗不导致原本不会发生的感染这一单调性假设下提出三类敏感性分析方法。
材料陈述的贡献
摘要称,研究提供非参数、半参数和参数方法,处理感染后可能右删失的事件结局,并应用于一项 HIV 疫苗三期试验。
阅读关注点
应核对始终感染主层的识别、单调性假设的含义,以及敏感性参数、删失条件和三类方法对额外假设的依赖。
阅读边界
仅据版本未注明的 OpenAlex 索引摘要;敏感性参数、完整识别与删失条件及试验结果未说明,随机化不足以直接消除子群选择问题。

原文摘要

In some randomized studies, researchers are interested in determining the effect of treatment assignment on outcomes that may exist only in a subset chosen after randomization. For example, in preventative human immunodeficiency virus (HIV) vaccine efficacy trials, it is of interest to determine whether randomization to vaccine affects postinfection outcomes that may be right-censored. Such outcomes in these trials include time from infection diagnosis to initiation of antiretroviral therapy and time from infection diagnosis to acquired immune deficiency syndrome. Here we present sensitivity analysis methods for making causal comparisons on these postinfection outcomes. We focus on estimating the survival causal effect, defined as the difference between probabilities of not yet experiencing the event in the vaccine and placebo arms, conditional on being infected regardless of treatment assignment. This group is referred to as the always-infected principal stratum. Our key assumption is monotonicity-that subjects randomized to the vaccine arm who become infected would have been infected had they been randomized to placebo. We propose nonparametric, semiparametric, and parametric methods for estimating the survival causal effect. We apply these methods to the first Phase III preventative HIV vaccine trial, VaxGen's trial of AIDSVAX B/B.

笔记与分组
相关领域论文